{"id":"NCT02227706","sponsor":"Ethicon, Inc.","briefTitle":"The Paediatric EVICEL® Soft Tissue and Parenchymal Organ Bleeding Study","officialTitle":"A Prospective, Randomized, Controlled Study Evaluating EVICEL® Fibrin Sealant as an Adjunct to Haemostasis During Abdominal, Retroperitoneal, Pelvic or Thoracic (Non-Cardiac) Surgery in Paediatric Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-08-01","primaryCompletion":"2019-04-17","completion":"2019-05-17","firstPosted":"2014-08-28","resultsPosted":"2020-08-31","lastUpdate":"2020-08-31"},"enrollment":40,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemorrhage","Soft Tissue Bleeding"],"interventions":[{"type":"BIOLOGICAL","name":"EVICEL® Fibrin Sealant","otherNames":["EVICEL, fibrin sealant"]},{"type":"DEVICE","name":"SURGICEL® Absorbable Hemostat","otherNames":["oxidized regenerated cellulose"]}],"arms":[{"label":"EVICEL® Fibrin Sealant","type":"EXPERIMENTAL"},{"label":"SURGICEL® Absorbable Hemostat","type":"ACTIVE_COMPARATOR"}],"summary":"To evaluate the safety and effectiveness of EVICEL® Fibrin Sealant (Human) as an adjunct to achieve haemostasis during surgery in paediatric patients.","primaryOutcome":{"measure":"Absolute Time to Haemostasis","timeFrame":"From randomisation (identification of appropriate target bleeding site) to final fascial closure (median study procedure time 164.0 minutes [range 47.0 - 506.0 minutes])","effectByArm":[{"arm":"EVICEL®","deltaMin":4,"sd":null},{"arm":"SURGICEL®","deltaMin":4,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":13,"countries":["Belgium","Canada","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":20},"commonTop":["Pyrexia","Procedural pain","Tachycardia","Vomiting","Abdominal pain"]}}